ReturnScreener

Dividend Record

CONCORDBIODividend History & Yield

Concord Biotech Ltd.

Concord Biotech Ltd. paid ₹18 a share over the last twelve months, a yield of 1.23%, and has now paid in 2 consecutive years.

Trailing yield
1.23%
Paid last year
₹18
Unbroken years
2
Yield on 10y cost

Price vs Dividends

How much of CONCORDBIO's return came from dividends

A share price tells you only half the story for a company that pays. Over the last 3 years Concord Biotech Ltd.'s quoted price moved +52.1%, but a holder who reinvested every dividend ended on +54.8% — which makes dividends 5% of everything the stock returned.

PeriodPrice returnDividends addedTotal returnFrom dividends
1 year-11.9%+1.1 pts-10.8%
3 years+52.1%+2.8 pts+54.8%5%

“Dividends added” is in percentage points of total return, with dividends treated as reinvested at the time they were paid — which is why it compounds and grows faster than the raw cash paid out. “From dividends” is shown only where the total return was positive; against a loss it would be a share of a negative number and would mean nothing.

Payout Record

CONCORDBIO dividend history, year by year

Per share, by the calendar year the dividend went ex — 3 years on record.

YearPer sharePaymentsRelative size
2026₹81
2025₹111
2024₹91

Grouped by calendar year rather than financial year, because that is how the ex-dates arrive in the data. A year with an unusually large figure often contains a special dividend rather than a raised regular one.

Dividend Income

What CONCORDBIO would pay on your holding

Based on the last twelve months of declared dividends. A company can cut or raise its payout at any time, so this is a record of what it recently paid, not an income you can count on.

InvestedA year at today's price
₹1.00L₹1,230
₹5.00L₹6,150
₹10.00L₹12,300
₹25.00L₹30,750
₹50.00L₹61,500

HELP CENTER

CONCORDBIO dividends — common questions

Everything you need to know about this page and the data presented.

How much dividend does CONCORDBIO pay?
+

Concord Biotech Ltd. paid ₹18 per share in dividends over the last twelve months, a yield of 1.23% against the current share price. It has paid in 3 separate calendar years across the history we hold, totalling ₹27 per share.

What is the dividend yield of CONCORDBIO?
+

CONCORDBIO's trailing dividend yield is 1.23% — the last twelve months of declared dividends divided by the current share price. Yield moves inversely with the price, so a falling share price raises the yield without the company paying a rupee more. That is why the payout record below matters more than the headline number.

Has CONCORDBIO paid dividends consistently?
+

Concord Biotech Ltd. has paid in 2 consecutive years, counting back from the last complete calendar year. A streak is a better guide to a company's intent than a single year's yield, which can be inflated by a one-off special dividend. It is still a record of the past — a payout can be cut at any time, and several long-running Indian payers have done exactly that.

How much of CONCORDBIO's return came from dividends?
+

Over the last 3 years CONCORDBIO's share price moved +52.1% while a holder reinvesting dividends earned +54.8% — so dividends account for about 5% of the total return. Almost every site quotes only the price change, which understates what a dividend payer actually returned.

When did CONCORDBIO last pay a dividend?
+

The most recent dividend on record went ex on 2026-07-24, at ₹8 per share. In 2026 it has paid 1 time, totalling ₹8 per share. Dates are ex-dividend dates from our price data, not the credit date — the money reaches a shareholder some weeks later.

Explore Further

More on Concord Biotech Ltd.

Dividend figures come from our price data provider's recorded ex-dates and are per share, before tax. Dividends in India are taxed in the recipient's hands and TDS may apply — nothing here accounts for that. ReturnScreener is an educational research platform and is not a SEBI-registered investment adviser. A payout can be cut or suspended at any time; past dividends are not a forecast of future ones. See our methodology and disclaimer.